Fredun Pharmaceuticals Limited

NSE: FREDUN · Unclassified

₹1,472.60-1.63%06 Nov 2026

Ask the data

Instant answers about Fredun Pharmaceuticals Limited — computed from its filings, no language model

Market cap₹350 cr

Current price₹1,472.60

High / Low₹1,552 / ₹1,222

P/E7.9

P/B—

Book value—

ROE—

ROCE—

Debt / equity—

Dividend yield—

EPS (TTM)₹187.16

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 10 periods

	FY17†	FY18†	FY19†	FY20†	FY21†	FY22†	FY23†	FY24†	FY25†	FY26†
Revenue	58.6	58.2	95.4	110.4	131.6	221.7	274.3	346.6	451.7	633.3
EBITDA	5.4	4.4	9.2	5.7	6.8	11.1	28.1	36.4	50.5	89.0
Operating margin	9.2%	7.5%	9.7%	5.2%	5.2%	5.0%	10.2%	10.5%	11.2%	14.1%
Interest	1.9	1.9	3.1	4.3	4.2	4.7	9.3	13.7	22.4	39.3
Depreciation	1.1	1.3	1.3	1.9	2.0	2.2	2.8	3.8	4.5	7.9
Profit before tax	2.3	2.6	6.2	2.5	3.2	8.6	18.1	21.4	28.3	47.6
Tax	0.8	0.9	1.7	0.6	0.3	2.3	6.7	5.8	7.5	9.5
Net profit	1.5	1.8	4.5	1.9	2.9	6.3	11.4	15.6	20.8	38.0

Quarterly performance

last 43 quarters · ₹ crore

showing latest 8 of 43 periods

	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†	JUN '19†	SEP '19†	DEC '19†	MAR '20†	JUN '20†	SEP '20†	DEC '20†	MAR '21†	JUN '21†	SEP '21†	DEC '21†	MAR '22†	JUN '22†	SEP '22†	DEC '22†	MAR '23†	JUN '23†	SEP '23†	DEC '23†	MAR '24†	JUN '24†	SEP '24†	DEC '24†	MAR '25†	JUN '25†	SEP '25†	DEC '25†	MAR '26†	JUN '26†
Revenue	12.9	16.0	16.7	10.4	13.9	17.7	9.3	15.0	13.7	20.2	16.2	21.8	26.3	31.1	28.3	31.4	26.2	24.4	13.3	32.1	45.1	41.1	44.8	54.4	53.1	69.5	48.1	68.8	77.7	79.7	61.2	81.5	86.7	117.2	77.5	106.9	101.8	165.4	119.4	143.6	159.9	210.4	227.8
Operating profit	1.0	2.4	1.3	1.1	0.7	2.2	1.0	1.1	0.8	1.4	-0.1	2.5	3.0	3.8	2.0	1.8	0.8	1.1	0.8	1.9	2.6	1.6	1.2	3.7	3.2	3.0	3.6	5.3	7.0	12.2	6.8	9.1	10.2	10.3	9.2	13.5	12.4	15.5	16.5	20.6	25.3	26.5	32.3
Operating margin	7.5%	14.7%	8.0%	10.6%	5.2%	12.5%	11.2%	7.6%	5.9%	6.9%	-0.5%	11.6%	11.3%	12.3%	7.0%	5.7%	3.2%	4.5%	6.0%	5.8%	5.7%	3.8%	2.6%	6.8%	6.1%	4.3%	7.4%	7.7%	9.0%	15.3%	11.1%	11.2%	11.7%	8.8%	11.9%	12.6%	12.1%	9.4%	13.9%	14.4%	15.8%	12.6%	14.2%
Other income	—	—	—	—	—	—	—	0.5	0.2	0.8	0.3	0.3	0.3	1.2	0.0	0.5	1.6	0.9	0.5	1.5	0.5	1.3	0.4	0.4	1.1	2.4	0.3	1.5	0.3	0.1	0.8	0.5	0.3	0.8	1.3	0.5	0.9	2.0	0.5	1.7	1.0	2.6	0.5
Interest	0.5	0.8	0.4	0.5	0.4	0.6	0.4	0.7	0.5	0.3	0.3	0.4	0.6	1.8	1.3	0.9	1.0	1.1	0.8	0.9	1.2	1.3	0.6	1.1	1.2	1.7	1.9	1.9	1.9	3.5	2.6	2.9	3.8	4.4	3.9	5.3	5.0	8.2	6.5	7.7	10.6	14.5	8.6
Depreciation	0.1	0.4	0.2	0.2	0.2	0.5	0.2	0.3	0.3	0.4	0.5	0.2	0.3	0.3	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.7	0.7	0.7	0.7	0.9	0.9	1.0	1.0	1.1	1.1	1.1	1.2	1.4	1.6	1.8	3.1	3.6
Profit before tax	0.3	1.1	0.8	0.3	0.1	1.1	0.5	0.5	0.2	1.5	-0.6	2.3	1.7	2.8	0.2	0.9	1.0	0.4	0.0	0.8	1.3	1.0	0.4	2.5	2.6	3.1	1.3	4.2	4.6	8.0	4.1	5.8	5.8	5.8	5.5	7.6	7.1	8.0	9.0	13.0	14.0	11.5	20.6
Tax	0.0	0.7	0.1	0.0	0.0	0.7	0.1	0.1	0.0	0.7	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.3	0.1	0.7	0.7	0.8	0.4	1.1	1.2	4.1	1.7	1.8	1.5	0.8	1.4	3.3	1.8	1.0	2.3	3.3	3.5	0.5	7.4
Net profit	0.3	0.4	0.6	0.3	0.1	0.5	0.4	0.4	0.2	0.7	-0.6	2.3	1.7	1.1	0.2	0.9	1.0	-0.2	0.0	0.8	1.3	0.7	0.3	1.8	1.9	2.3	0.9	3.1	3.5	3.9	2.4	3.9	4.2	5.1	4.1	4.3	5.3	7.1	6.8	9.7	10.5	11.1	13.2
EPS ₹	1.17	1.64	2.56	1.38	0.59	1.82	1.56	1.47	0.69	2.13	—	5.64	4.28	2.80	0.59	2.20	2.55	-0.54	0.09	2.07	3.35	1.82	0.82	4.61	4.22	5.18	2.12	7.11	7.66	8.59	5.24	8.40	8.99	10.77	8.79	9.05	11.29	0.00	0.00	0.00	0.00	0.00	0.00
Revenue YoY	—	—	—	—	7.4%	10.5%	-44.2%	45.0%	-1.6%	14.4%	74.7%	45.2%	92.1%	53.7%	74.2%	43.9%	-0.1%	-21.4%	-53.2%	2.0%	71.9%	68.4%	238.0%	69.5%	17.8%	68.9%	7.4%	26.7%	46.2%	14.8%	27.2%	18.4%	11.6%	47.0%	26.6%	31.2%	17.5%	41.1%	54.0%	34.3%	57.0%	27.2%	90.8%
Profit YoY	—	—	—	—	-50.0%	17.9%	-39.3%	33.3%	42.9%	60.9%	-270.3%	413.6%	755.0%	51.4%	—	-61.1%	-40.4%	-118.8%	-82.6%	-5.7%	31.4%	—	725.0%	121.7%	39.6%	215.1%	184.8%	71.2%	85.0%	69.1%	155.3%	25.1%	22.0%	30.1%	72.1%	8.4%	26.3%	39.7%	63.9%	127.9%	96.6%	56.6%	94.5%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 40 periods

	SEP '16	DEC '16	MAR '17	JUN '17	SEP '17	DEC '17	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Net margin	2.9%	2.6%	2.6%	2.5%	2.5%	2.6%	3.0%	1.2%	3.6%	4.8%	4.7%	4.9%	3.4%	2.8%	1.7%	1.8%	1.8%	1.7%	2.2%	2.0%	2.3%	2.5%	2.9%	3.1%	3.4%	3.7%	4.2%	4.5%	4.6%	4.7%	4.5%	4.8%	4.6%	4.7%	4.6%	4.7%	5.5%	5.8%	6.0%	6.0%
EBITDA margin	10.3%	9.7%	9.2%	9.9%	9.1%	9.3%	7.5%	5.0%	6.5%	8.1%	9.7%	10.5%	9.0%	7.2%	5.2%	4.8%	4.8%	5.5%	5.2%	4.4%	4.8%	5.0%	5.0%	6.0%	6.3%	7.2%	10.2%	10.9%	11.7%	12.4%	10.5%	10.7%	11.1%	11.3%	11.2%	11.7%	12.3%	13.3%	14.1%	14.1%
Interest coverage	2.08	2.09	2.24	2.09	2.07	2.01	2.36	1.81	3.15	4.01	2.99	2.74	2.23	1.99	1.58	1.61	1.60	1.64	1.77	1.90	2.27	2.54	2.85	2.60	2.66	2.78	2.96	3.10	3.04	2.84	2.57	2.53	2.42	2.40	2.26	2.27	2.36	2.34	2.21	2.43

Balance sheet

equity vs borrowings over time · ₹ crore

Not filed yet.

Cash flow

annual · ₹ crore · line = free cash flow

Not filed yet.

Where the assets sit

No balance sheet filed yet.

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Fredun Pharmaceuticals Limited	350	1,472.60	7.9	—	—

StoxGud checklist: Neutral setup · 4/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-0.1%

6 months—

1 year—

3Y CAGR—

5Y CAGR—

10Y CAGR—

50-day avg₹1,424.79

200-day avg—

RSI (14)50

FAQs

What is the share price of Fredun Pharmaceuticals Limited?

Fredun Pharmaceuticals Limited (FREDUN) closed at ₹1,472.60 on NSE on 06 Nov 2026.

What is the market cap of Fredun Pharmaceuticals Limited?

₹350 crore at the latest close.

What is the P/E ratio of Fredun Pharmaceuticals Limited?

7.9, on trailing-twelve-month earnings from its filings.

How fast is Fredun Pharmaceuticals Limited growing?

Fredun Pharmaceuticals Limited: revenue has compounded at 32.2% a year over three years; net profit at 49.3% a year. Latest-quarter revenue is up 90.8% year on year, profit up 94.5%.

How profitable is Fredun Pharmaceuticals Limited?

On a trailing-twelve-month basis operating margin 14.1%, net margin 6.0%.

How much debt does Fredun Pharmaceuticals Limited have?

Debt to equity isn't meaningful for Fredun Pharmaceuticals Limited (banks borrow as part of their business) or isn't filed yet.

Fredun Pharmaceuticals Limited's results are not in NSE's XBRL filings, so these are its standalone quarterly results as published on BSE (†), ₹ crore, from DEC '15; full years are summed from the quarters. No balance sheet or cash flow is available from this source. Information only, not investment advice.